Pharmaceutical News

RSS

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

New breakthrough drug shows promise to fight antibiotic-resistant infections

A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections.

28 Jan 2016

Using painkillers during pregnancy may harm fertility of daughters

Using painkillers in pregnancy may reduce fertility in subsequent generations, research suggests. Tests in rats found that when a mother was given painkillers during pregnancy, her female offspring had fewer eggs, smaller ovaries and smaller litters of babies than those not exposed to the drugs.

28 Jan 2016

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

PAHO recommendations for preventing or slowing spread of Zika virus

Zika is a mosquito-borne virus that is new to the Americas. Since Brazil reported the first cases of local transmission of the virus in May 2015, it has spread to 21 countries and territories* of the Americas (as of 23 January 2016).

27 Jan 2016

Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC.

25 Jan 2016

Opioid medication does not improve physical function in patients with neuropathic pain

Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning compared to those who were not prescribed opioids.

25 Jan 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

Scientists demonstrate effectiveness of ART in HIV-infected infants

Recent clinical trials conducted in South Africa have established that babies born with HIV should be treated with antiretroviral therapy (ART) as early as possible, since earlier treatment significantly decreases their mortality and morbidity rates.

25 Jan 2016

Epidural analgesia has some adverse effects on newborns

Researchers from the University of Granada observed that babies born after epidural analgesia show a small decline in Apgar index values, a quick test applied to newborn babies in order to assess their general health.

25 Jan 2016

Oestrogen supplements could reduce dementia risk in women

Women who take oestrogen supplements from before or at the start of menopause and continue with them for a few years have better preserved brain structure, which may reduce the risk of dementia.

22 Jan 2016

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain.

22 Jan 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Pharmaceutical News

Halaven (eribulin mesylate) approved for treatment of liposarcoma

New breakthrough drug shows promise to fight antibiotic-resistant infections

Using painkillers during pregnancy may harm fertility of daughters

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

PAHO recommendations for preventing or slowing spread of Zika virus

Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Opioid medication does not improve physical function in patients with neuropathic pain

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Scientists demonstrate effectiveness of ART in HIV-infected infants

Epidural analgesia has some adverse effects on newborns

Oestrogen supplements could reduce dementia risk in women

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Aged Garlic Extract beneficial for preventing heart disease

Oxeia accelerating development of neurometabolic treatments for concussions

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News